Administration

IGC Pharma Reports Third Quarter Fiscal 2024 Results

Retrieved on: 
Saturday, February 17, 2024

IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024).

Key Points: 
  • IGC Pharma, Inc. (“IGC” or the “Company”) (NYSE American: IGC) today announced its financial results for the third fiscal quarter of 2024 ended December 31, 2023 (Q3 FY 2024).
  • IGC is optimistic that the success in Mexico can pave the way for additional patent approvals in the U.S. and Europe.
  • We are working hard to obtain interim results in 2024.
  • With modest pricing and conservative market penetration IGC-AD1 can potentially be a block buster drug,” said Ram Mukunda, CEO of IGC Pharma.

Notice convening the Annual General Meeting of AB Electrolux

Retrieved on: 
Friday, February 16, 2024

The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.

Key Points: 
  • The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.
  • The principles shall be applied to employment and consultancy agreements entered into after the 2024 Annual General Meeting, and to changes made to existing agreements thereafter.
  • The proposal to the 2024 Annual General Meeting for resolution on guidelines for remuneration corresponds, in all material aspects, with the guidelines adopted by the 2020 Annual General Meeting.
  • The resolution of the Annual General Meeting to implement the Share Program 2024 according to a) above requires that more than half of the votes cast at the Annual General Meeting are in favor of the proposal.

Notice convening the Annual General Meeting of AB Electrolux

Retrieved on: 
Friday, February 16, 2024

The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.

Key Points: 
  • The Board of Directors proposes that the following guidelines for remuneration shall be approved by the Annual General Meeting of the Company.
  • The principles shall be applied to employment and consultancy agreements entered into after the 2024 Annual General Meeting, and to changes made to existing agreements thereafter.
  • The proposal to the 2024 Annual General Meeting for resolution on guidelines for remuneration corresponds, in all material aspects, with the guidelines adopted by the 2020 Annual General Meeting.
  • The resolution of the Annual General Meeting to implement the Share Program 2024 according to a) above requires that more than half of the votes cast at the Annual General Meeting are in favor of the proposal.

NCLA Amicus Brief Exposes Fatal Constitutional Flaws in SEC’s Illegal Mass Data Collection Regime

Retrieved on: 
Thursday, February 15, 2024

SEC’s CAT is an unprecedented mass confiscation of personal financial data in blatant violation of the Fourth Amendment’s restrictions on unreasonable searches and seizures.

Key Points: 
  • SEC’s CAT is an unprecedented mass confiscation of personal financial data in blatant violation of the Fourth Amendment’s restrictions on unreasonable searches and seizures.
  • No law passed by Congress gives SEC authority to set up a data collection and surveillance system.
  • NCLA released the following statements:
    “The CAT is an illegal SEC power grab that violates ordinary Americans’ basic constitutional rights.
  • This Leviathan-sized dragnet is absurd, risky, and utterly unlawful.”
    — Mark Chenoweth, President and Chief Legal Officer, NCLA

Dynamic Announces Brian Paplaski as Chief Financial Officer and Further Additions to the Executive Team

Retrieved on: 
Thursday, February 15, 2024

Mr. Paplaski brings extensive experience and a demonstrated track record to Dynamic and will lead the Company’s corporate finance functions.

Key Points: 
  • Mr. Paplaski brings extensive experience and a demonstrated track record to Dynamic and will lead the Company’s corporate finance functions.
  • Mr. Paplaski has a long history of bringing financial rigor to successfully build businesses, having held numerous CFO positions throughout his career.
  • “Brian is a proven financial executive with a strong track record steering financial growth and strategic initiatives.
  • He is a results-driven financial leader who will bring great value to the platform,” said Aaron Johnson, CEO at Dynamic.

Prelude Therapeutics Reports Full Year 2023 Financial Results and Outlines Key Objectives for 2024

Retrieved on: 
Thursday, February 15, 2024

WILMINGTON, Del., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today reported its financial results for the fiscal year ended December 31, 2023, and outlined key objectives for 2024.   

Key Points: 
  • “Our partnership with AbCellera represents a strategic step to expand our pipeline, based on our core competencies in medicinal chemistry, cancer biology and clinical development.
  • A second cohort of patients with AML is expected to initiate in the first half of 2024.
  • Under the terms of the agreement, Prelude and AbCellera will jointly discover, develop, and commercialize products emerging from the collaboration.
  • The decrease in general and administrative expenses was primarily due to our continued management of general and administrative expenses.

Riley Goodman Promoted to VP, Finance and Information Technology at FTK

Retrieved on: 
Thursday, February 15, 2024

FTK Construction Services, a nationwide General Contractor specializing in Affordable Housing/LIHTC projects, is pleased to announce the promotion of Riley Goodman to Vice President of Finance and Information Technology.

Key Points: 
  • FTK Construction Services, a nationwide General Contractor specializing in Affordable Housing/LIHTC projects, is pleased to announce the promotion of Riley Goodman to Vice President of Finance and Information Technology.
  • Goodman steps into his new role after previously holding the Director of Financial Operations position for FTK.
  • Goodman received his Bachelor of Science in Finance with a focus on financial analysis and investment from the University of Arkansas.
  • View the full release here: https://www.businesswire.com/news/home/20240215628226/en/
    FTK is pleased to announce the promotion of Riley Goodman to Vice President of Finance and Information Technology.

Agios Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Thursday, February 15, 2024

CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today reported business highlights and financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Launch: Generated $7.1 million in U.S. net revenue for the fourth quarter of 2023, a 4 percent decrease from the third quarter of 2023, primarily driven by lower customer inventory levels at the end of the fourth quarter of 2023, partially offset by favorable gross-to-net adjustments.
  • A total of 109 patients are on PYRUKYND® therapy, a 9 percent increase from the third quarter of 2023.
  • Cost of Sales: Cost of sales was $0.6 million for the fourth quarter of 2023 and $2.9 million for the full year ended Dec. 31, 2023.
  • ET to discuss fourth quarter and full year 2023 financial results and recent business highlights.

Kaival Brands Provides Business Update in Letter to Shareholders

Retrieved on: 
Wednesday, February 14, 2024

Operating Expenses decreased to $13.2 million compared to $15.6 million, with the decrease driven primarily by disciplined cost management.

Key Points: 
  • Operating Expenses decreased to $13.2 million compared to $15.6 million, with the decrease driven primarily by disciplined cost management.
  • As of October 31, 2023, Kaival Brands had working capital of approximately $1.9 million and total cash of approximately $0.5 million.
  • Through it all, we remain committed to steadfast compliance with established FDA requirements for our products and business as we have since our inception.
  • Those ten products remain available for sale through Kaival Brands, subject to FDA’s enforcement discretion.

Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

Retrieved on: 
Wednesday, February 14, 2024

SARASOTA, FL, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today provided a positive update on SP-26, its novel time-released, dose-controlled formulation of ketamine initially targeted for fibromyalgia. A pre-clinical research study is underway involving analytical testing services and small batch proof-of-concept extrusion trials to determine drug release and stability.

Key Points: 
  • A pre-clinical research study is underway involving analytical testing services and small batch proof-of-concept extrusion trials to determine drug release and stability.
  • In recent testing, SP-26 polymer implants were blended with ketamine hydrochloride (ketamine HCL) in two loadings, 20% and 40%.
  • “Implantable drug delivery systems like SP-26 may provide sustained drug delivery for prolonged periods of time, which is critical for the treatment of chronic pain conditions,” said Eric Weisblum, CEO of Silo.
  • Silo believes that implantable drug delivery systems (IDDS) can offer a superior delivery alternative for sustained relief from chronic pain.